[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595254":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":32,"collaborators":7,"id":36,"slug":7,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":7,"maxAge":7,"enrollmentInfo":43,"targetDuration":46,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Xiangbin Pan, MD","CONTACT","88396655","panxiangbin@fuwaihospital.org",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":7},"Fengwen Zhang, MD","88396654",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Fuwai Hospital","RECRUITING","Beijing","100037","China",{"type":25,"coordinates":26},"Point",[27,28],116.39723,39.9075,{"lat":28,"lon":27},[31],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Pan Xiangbin","Principle Investigator","100595254",false,"NCT07030062","Echocardiography Guided TAVR (Echo TAVR)","Transcatheter Aortic Valve Replacement With Echocardiography Guidance","Inclusion Criteria:\n\n1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m\u002Fs, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2\u002Fm2);\n2. a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures;\n3. chronic kidney disease and refuse to receive contrast agents or radiation exposure.\n\nExclusion Criteria:\n\nRequired hybrid procedures or concomitant interventions on other cardiac malformations; Deemed inoperable due to extremely high surgical risk or severe comorbidities; Had untreated clinically significant coronary vascular disease amenable to revascularization; Previously undergone aortic valve replacement.","ALL",{"count":44,"type":45},20,"ESTIMATED","1 Month","OBSERVATIONAL","Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.",[50,51],"Transcatheter Aortic Valve Replacemen","Echocardiography","2025-06-12",{"date":54,"type":55},"2025-06-19","ACTUAL",{"date":57,"type":55},"2025-02-18",{"date":59,"type":45},"2025-12-31",{"name":34,"class":6},1]